Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting

Abstract Multiple classes of therapies targeting claudin-18 isoform 2 (CLDN18.2) are under development for the treatment of advanced gastroesophageal adenocarcinoma and other solid tumors. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the final results of the phase 3 SPOTL...

Full description

Bibliographic Details
Published in:Journal of Hematology & Oncology
Main Authors: Katherine I. Zhou, John H. Strickler, Hui Chen
Format: Article
Language:English
Published: BMC 2024-08-01
Subjects:
Claudin-18.2
Targeted therapies
Antibody therapies
Antibody–drug conjugates
Bispecific antibodies
Chimeric antigen receptor T cell therapy
Online Access:https://doi.org/10.1186/s13045-024-01595-w

Internet

https://doi.org/10.1186/s13045-024-01595-w

Similar Items